Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Sensipar / Mimpara (cinacalcet by Year
Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)
Amgen Sensipar / Mimpara (cinacalcet: $54M in FY2022, down 30.8% from a year earlier. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
“|| Sensipar/Mimpara — ROW | 54 | (31) | % | 78 | (60) | % | 196”
Source: Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 54 | -30.8% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 78 | -60.2% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 196 | -34.4% | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 299 | -11.5% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 338 | -1.7% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 344 | +0.6% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 342 | – | Form 10-K (filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Sensipar / Mimpara (cinacalcet ($M), annual FY2016–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-sensipar-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.